Insulin priming effect on estradiol-induced breast cancer metabolism and growth

References

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin 2011; 61:69-90; PMID:21296855
   PubMed Web of Science ®Google Scholar
• Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas 2001; 38:103-13; discussion 13-6; PMID:11311599; http://dx.doi.org/10.1016/S0378-5122(00)00196-1
   PubMed Web of Science ®Google Scholar
• Kaplan MA, Pekkolay Z, Kucukoner M, Inal A, Urakci Z, Ertugrul H, Akdogan R, Firat U, Yildiz I, Isikdogan A. Type 2 diabetes mellitus and prognosis in early stage breast cancer women. Med Oncol 2012; 29:1576-80; PMID:22083554; http://dx.doi.org/10.1007/s12032-011-0109-4
   PubMed Web of Science ®Google Scholar
• Cadoo KA, Fornier MN, Morris PG. Biological subtypes of breast cancer: current concepts and implications for recurrence patterns. Q J Nucl Med Mol Imag: Off Pub Ital Assoc Nucl Med 2013; 57:312-21; PMID:24322788
   PubMed Web of Science ®Google Scholar
• Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. The impact of diabetes on survival following breast cancer. Br Cancer Res Treat 2008; 109:389-95; PMID:17659440; http://dx.doi.org/10.1007/s10549-007-9654-0
   PubMed Web of Science ®Google Scholar
• Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care 2008; 31 Suppl 2:S262-8; PMID:18227495; http://dx.doi.org/10.2337/dc08-s264
   PubMedGoogle Scholar
• Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, Manson JE, Nurses' Health Study. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care 2003; 26:1752-8; PMID:12766105; http://dx.doi.org/10.2337/diacare.26.6.1752
   PubMed Web of Science ®Google Scholar
• Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009; 101:48-60; PMID:19116382; http://dx.doi.org/10.1093/jnci/djn415
   PubMed Web of Science ®Google Scholar
• He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee MH, Yeung SC. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer. Ann Oncol: Off J Eur Soc Med Oncol/ESMO 2012; 23:1771-80; PMID:22112968; http://dx.doi.org/10.1093/annonc/mdr534
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA: Cancer J Clin 2010; 60:207-21; PMID:20554718
   PubMed Web of Science ®Google Scholar
• Sachdev D, Yee D. The IGF system and breast cancer. Endocr-relat Cancer 2001; 8:197-209; PMID:11566611; http://dx.doi.org/10.1677/erc.0.0080197
   PubMed Web of Science ®Google Scholar
• Yee D, Lee AV. Crosstalk between the insulin-like growth factors and estrogens in breast cancer. J Mammary Gland Biol 2000; 5:107-15; PMID:10791773; http://dx.doi.org/10.1023/A:1009575518338
   PubMed Web of Science ®Google Scholar
• Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol 2005; 229:161-73; PMID:15607540; http://dx.doi.org/10.1016/j.mce.2004.08.002
   PubMed Web of Science ®Google Scholar
• Belfiore A, Frasca F. IGF and insulin receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 2008; 13:381-406; PMID:19016312; http://dx.doi.org/10.1007/s10911-008-9099-z
   PubMed Web of Science ®Google Scholar
• Bartella V, De Marco P, Malaguarnera R, Belfiore A, Maggiolini M. New advances on the functional cross-talk between insulin-like growth factor-I and estrogen signaling in cancer. Cell Signalling 2012; 24:1515-21; PMID:22481093; http://dx.doi.org/10.1016/j.cellsig.2012.03.012
   PubMed Web of Science ®Google Scholar
• Hawsawi Y, El-Gendy R, Twelves C, Speirs V, Beattie J. Insulin-like growth factor - oestradiol crosstalk and mammary gland tumourigenesis. Biochimica et Biophysica Acta 2013; 1836:345-53; PMID:24189571
   PubMed Web of Science ®Google Scholar
• Fox EM, Miller TW, Balko JM, Kuba MG, Sanchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, et al. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 2011; 71:6773-84; PMID:21908557; http://dx.doi.org/10.1158/0008-5472.CAN-11-1295
   PubMed Web of Science ®Google Scholar
• Madak-Erdogan Z, Lupien M, Stossi F, Brown M, Katzenellenbogen BS. Genomic collaboration of estrogen receptor alpha and extracellular signal-regulated kinase 2 in regulating gene and proliferation programs. Mol Cell Biol 2011; 31:226-36; PMID:20956553; http://dx.doi.org/10.1128/MCB.00821-10
   PubMed Web of Science ®Google Scholar
• Marquez DC, Pietras RJ. Membrane-associated binding sites for estrogen contribute to growth regulation of human breast cancer cells. Oncogene 2001; 20:5420-30; PMID:11571639; http://dx.doi.org/10.1038/sj.onc.1204729
   PubMed Web of Science ®Google Scholar
• Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011; 20:119-31; PMID:21741601; http://dx.doi.org/10.1016/j.ccr.2011.05.026
   PubMed Web of Science ®Google Scholar
• Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009; 69:6131-40; PMID:19638585; http://dx.doi.org/10.1158/0008-5472.CAN-09-0452
   PubMed Web of Science ®Google Scholar
• Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, Gerald WL. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25:3994-4008; PMID:16491124; http://dx.doi.org/10.1038/sj.onc.1209415
   PubMed Web of Science ®Google Scholar
• Chan SC, Li Y, Dehm SM. Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem 2012; 287:19736-49; PMID:22532567; http://dx.doi.org/10.1074/jbc.M112.352930
   PubMed Web of Science ®Google Scholar
• Bjornstrom L, Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 2005; 19:833-42; PMID:15695368; http://dx.doi.org/10.1210/me.2004-0486
   PubMed Web of Science ®Google Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11:85-95; PMID:21258394; http://dx.doi.org/10.1038/nrc2981
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324:1029-33; PMID:19460998; http://dx.doi.org/10.1126/science.1160809
   PubMed Web of Science ®Google Scholar
• Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 2008; 452:181-6; PMID:18337815; http://dx.doi.org/10.1038/nature06667
   PubMed Web of Science ®Google Scholar
• Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202:654-62; PMID:15389572; http://dx.doi.org/10.1002/jcp.20166
   PubMed Web of Science ®Google Scholar
• Miller RA, Chu QW, Xie JX, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013; 494:256-60; PMID:23292513; http://dx.doi.org/10.1038/nature11808
   PubMed Web of Science ®Google Scholar
• Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, Andreelli F. Cellular and molecular mechanisms of metformin: an overview. Clin Sci 2012; 122:253-70; PMID:22117616; http://dx.doi.org/10.1042/CS20110386
   PubMed Web of Science ®Google Scholar
• Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care 1990; 13:696-704; PMID:2162756; http://dx.doi.org/10.2337/diacare.13.6.696
   PubMed Web of Science ®Google Scholar
• Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr-Relat Cancer 2009; 16:1103-23; PMID:19620249; http://dx.doi.org/10.1677/ERC-09-0087
   PubMed Web of Science ®Google Scholar
• Iwase H, Kobayashi M, Nakajima M, Takatori T. The ratio of insulin to C-peptide can be used to make a forensic diagnosis of exogenous insulin overdosage. Forensic Sci Int 2001; 115:123-7; PMID:11056282; http://dx.doi.org/10.1016/S0379-0738(00)00298-X
   PubMed Web of Science ®Google Scholar
• Diaz-Delfin J, Morales M, Caelles C. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway. Diabetes 2007; 56:1865-71; PMID:17416798; http://dx.doi.org/10.2337/db06-1293
   PubMed Web of Science ®Google Scholar
• Jeong Y, Xie Y, Lee W, Bookout AL, Girard L, Raso G, Behrens C, Wistuba II, Gadzar AF, Minna JD, et al. Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer. Mol Endocrinol 2012; 26:1443-54; PMID:22700587; http://dx.doi.org/10.1210/me.2011-1382
   PubMed Web of Science ®Google Scholar
• Bookout AL, Cummins CL, Mangelsdorf DJ, Pesola JM, Kramer MF. High-throughput real-time quantitative reverse transcription PCR. Current Protocols in Molecular Biology, edited by Frederick M Ausubel [et al] 2006; Chapter 15:Unit 15 8. PMID:18265376; doi:10.1002/0471142727.mb1508s73
   Google Scholar